Sapigen Biologix Profile
Key Indicators
- Authorised Capital ₹ 630.00 Cr
as on 10-11-2024
- Paid Up Capital ₹ 624.00 Cr
as on 10-11-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 322.77 Cr
as on 10-11-2024
About Sapigen Biologix
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 630.00 Cr and a paid-up capital of Rs 624.00 Cr.
The company currently has active open charges totaling ₹322.77 Cr.
The Key Managerial Personnel (KMP) at Sapigen Biologix Private Limited India are Cherukupalli Kumar as COMPANY SECRETARY and Gopinathan Kumar as Cfo. Krishna Ella, Melappati Chakravarthy, Jalachari Ella, and One other member serve as directors at the Company.
- CIN/LLPIN
U73100OD2020PTC046324
- Company No.
144962
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sapigen Biologix?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raches Ella  | Managing Director | 17-Oct-2020 | Current |
| Cherukupalli Kumar | Company Secretary | 06-Jun-2024 | Current |
| Gopinathan Kumar | CFO | 03-Oct-2024 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Krishna Ella | Director | 17-Oct-2020 | Current |
| Melappati Chakravarthy | Director | 20-Feb-2023 | Current |
| Jalachari Ella | Director | 18-Mar-2021 | Current |
Financial Performance of Sapigen Biologix.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sapigen Biologix?
Unlock access to Sapigen Biologix's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Bharat Biotech International LimitedActive 28 years 10 monthsKrishna Ella and Melappati Chakravarthy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Mar 2022 | ₹122.77 Cr | Open |
State Bank Of India Creation Date: 27 Dec 2021 | ₹200.00 Cr | Open |
How Many Employees Work at Sapigen Biologix?
Unlock and access historical data on people associated with Sapigen Biologix, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sapigen Biologix, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sapigen Biologix's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
